Problem Although most primary hepatocellular cancers (HCCs) are attributable to chronic viral hepatitis and largely preventable, such cancers remain a leading cause of cancer-related mortality wherever chronic hepatitis B is endemic.
Problem
In May 2010, the Sixty-third World Health Assembly adopted a resolution calling for a comprehensive approach to the prevention and control of all forms of viral hepatitis -which kills over 1 million people each year. Human infection with hepatitis B virus is highly endemic in many Asian countries. 1 Such infection is generally acquired early in life and leads to lifelong chronic hepatitis B that has life-threatening complications -such as cirrhosis and hepatocellular cancers (HCCs) -in 25 to 40% of cases. [2] [3] [4] Over 200 000 Australians are estimated to have chronic hepatitis B 5 and liver cancer is now the seventh most common cause of cancer-related death among Australian men. 6 In Australia, despite these observations, there is no systematic screening for chronic hepatitis B, even among at-risk groups, and many cases of the disease are only detected late, after the onset of complications. In New South Wales -Australia's most populous state -46% of HCCs occur among immigrants, particularly those born in countries with endemic hepatitis B. 7 Compared with individuals born in Australia, immigrants from China, Indonesia, the Republic of Korea or
Viet Nam have a six-to 12-fold greater risk of developing HCCs. 7 In addition to vaccination, the public health response to hepatitis B requires screening for the chronic form of the disease, improved access to care and support and improved training, education and disease surveillance. To address these challenges as they apply to New South Wales, a local cancer charity -Cancer Council New South Wales -planned and implemented a multi-pronged intervention designed to reduce the incidence of hepatitis-B-related liver cancer among the state's high-risk migrant communities. The main pillars of this intervention, which is known as the "B Positive" programme, comprise economic modelling to ascertain the programme's costs and benefits, educational outreach for both the at-risk migrant communities and their primary-care providers and the establishment of a registry for cases of chronic hepatitis B. The registry has been developed to improve not only our understanding of the epidemiology of chronic hepatitis B, but also the follow-up of participants in the B Positive programme. The programme's key activities and some of the lessons learnt as a result of the programme are summarized below.
Approach
The programme was approved by the Institutional Ethics Committee of the Sydney South West
Area Health Service and developed in three phases. In Phase 1, economic modelling was used to investigate the feasibility of the programme. The target population was defined, a screening and treatment algorithm for chronic hepatitis B was developed and the types of data to be recorded in the disease registry were determined.
The programme's target population consists of residents of south-west Sydney born in countries with high prevalences of hepatitis B and who receive primary health care from local general practitioners. However, the programme has also been made available to all local have high viral loads but normal levels of ALT. General practitioners are encouraged to refer the high-risk cases for specialist assessment and to continue to follow up the other cases. 8 In Phase 2, the programme's acceptability to key stakeholders was ascertained. In addition, opportunities for the education of local general practitioners and target communities about hepatitis B testing, prevention and treatment were provided.
In Phase 3 of the programme's development, an extensive programme redesign was implemented based on consultation with the relevant stakeholders. The monitoring and evaluation tools were refined and the data collected in the case registry were compared against the assumptions made in the economic modelling.
Local setting HCC; HCC prevention -in which enhanced HCC surveillance was combined with the optimized management of chronic hepatitis B; and maintenance of the status quo -which was characterized by low levels of treatment uptake for chronic hepatitis B and only opportunistic screening for HCC. For each modelled strategy, case stratification and management were based on age, viral load and ALT level. We modelled a hypothetical cohort of 10 000 Asian-born adults with chronic hepatitis B; all were aged 35 years at enrolment and were followed up for 50 years. The cost, the number and proportion of cases of HCC averted, the number of deaths averted and the number of quality-adjusted life years gained over the entire follow-up period were estimated for each strategy. We adopted a health-care funder perspective and discounted all future costs and health outcomes by 5% per year.
Only one of the three strategies modelled -HCC prevention -appeared to be costeffective and able to deliver substantial health benefits. In the model, this strategy reduced cases of cirrhosis, HCC diagnoses and hepatitis-B-related deaths over the 50 years of follow-up by 52%, 47% and 56%, respectively, at an estimated cost of 12 956 Australian dollars for each quality-adjusted life year gained. 8 As a consequence of this modelling work, the B Positive programme used the HCC-prevention approach.
The programme has only led to a slight increase in the workloads of the general practitioners who serve the target communities. It has, however, substantially increased the local demand for the specialist services needed in the management of HCC, 9 even though most cases of chronic hepatitis B enrolled in the programme can be managed at the primary-care level. Only 8 to 25% of cases -the exact proportion depending on the guidelines that are followed for treatment initiation -require antiviral treatment. 10 However, in the economic modelling, the cost of antiviral drugs accounted for most (54-76%) of the estimated total cost of the programme. 10 The economic modelling showed that the estimated costs attributed to surveillance for chronic hepatitis B (4-30% of the programme's total cost) and HCC screening and surveillance (5-9%)
were relatively small. The programme's relaunch also entailed revisions to our interventions for improving community engagement. We consulted widely to ensure that our community-level educational activities were culturally sensitive and adequately tailored to the target communities. We also established collaborations with key community-based organizations, local councils and schools.
Messages designed to improve screening for hepatitis B are now widely disseminated at community meetings, festivals and fairs and marketed through "ethnic" newspapers, newsletters and radio programmes. Differential messaging is used for specific audiences -such as students from Viet Nam, we produced a soap-opera-style film in Vietnamese. The actors in this film were local residents and important messages about hepatitis B were weaved into the storyline.
Although this film has only been shown in two cinemas, it is envisaged that it will be distributed more widely and, perhaps, broadcast on at least one local television channel. Local high-school students learn about hepatitis B as they are taught about film animation and convey messages about hepatitis B prevention to their peers, families and communities.
Over the last 12 months, the number of individuals enrolled in the hepatitis registry has increased substantially. At the time of writing, more than 1200 cases -approximately 15% of the entire target population -are enrolled and being followed up by more than 50 local general practitioners.
The recent effectiveness of the B Positive programme was highlighted by the results of a nationwide survey on the uptake of treatment by cases of chronic hepatitis B in Australia. The percentage of such cases in south-west Sydney who were receiving treatment (7%) was found to be higher than that in any other surveyed area and double the nationalaverage. 12 
Lessons learnt
The main lessons learnt from the B Positive programme (Box 1) indicate that a public health intervention to tackle chronic hepatitis B and its complications can be feasible, acceptable to the target communities and effectively delivered by trained general practitioners. The initial problem of low programme uptake was corrected by a wide consultation and a substantial redesign of the programme -highlighting the critical role of ongoing monitoring and stakeholder consultations in the success of this and similar programmes.
The interventions implemented in the B Positive programme are similar to those followed in similar large-scale, community-based programmes in New Zealand 13 and the United States of America. 14, 15 The B Positive programme has been seeking to reduce hepatitis-B-related health disparities in migrant populations through community-based screening, linkage to care and Publication: Bulletin of the World Health Organization; Type: Lessons from the field Article ID: BLT.13.130344
increasing community-level awareness of hepatitis B and participation in disease surveillance.
Meaningful community engagement has played a critical role in the programme's success.
Without such engagement and adequate input from the "recipient" communities, programme uptake would probably have been too poor to have had a significant impact on any hepatitis-Brelated health problem. Whitehead identified a spectrum of community-based interventionsranging from those where the community is the driver and funding agent to those controlled by external agencies -in which the establishment of equitable and mutually rewarding partnerships represented the "ideal" scenario. 16 The original B Positive programme was launched with limited community involvement, with the target communities being the programme's recipients but having little opportunity to contribute to the programme's design. Only after the programme's goals were clearly communicated and the scope of community consultation was widened did the programme's aims become relevant to the target communities -resulting in increased programme uptake.
As far as we are aware, B Positive is the only population-based programme for chronic hepatitis B mitigation guided by economic modelling and using a case registry to support patient follow-up and linkage to treatment. In the absence of systematic surveillance for chronic hepatitis B in Australia, data collected in our case registry are helping to characterize the clinical features, staging and treatment needs of people with the disease.
In chronic hepatitis B, the high cost of antiviral therapy currently makes the treatment of all cases identified in population-based screenings unaffordable in many countries. However, it appears that only a relatively small proportion of those diagnosed with the disease require antiviral treatment and that cases needing antiviral therapy can be effectively identified by a system for screening and follow-up. The data collected in the B Positive programme indicate that, among high-risk groups, such a system can be fairly readily implemented at primary-care level, at an acceptable cost. We envisage that community-based screening for chronic hepatitis B and community-based treatment will soon become a reality, even in resource-limited settings.
As the building of adequate community trust requires careful planning and much lead time, it appears unreasonable to defer public health action against chronic hepatitis B until antiviral treatment becomes less costly. Today's challenge is to move beyond demonstration projects to full-scale implementation. This is reminiscent of the state of affairs seen in the management of human immunodeficiency virus (HIV) a decade ago, as summarized by Moatti et al.: "Scaling up access to antiretroviral drugs (ARVs) for HIV-infected adults and children in developing countries can no longer be refused for medical or economic reasons, or on the grounds of inequality, lack of infrastructure, risk of viral resistance or alternative priorities.
Access to ARVs is an appropriate, rational and cost-effective investment choice in developing countries."
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• As the costs of screening for chronic hepatitis B and follow-up are relatively low and less than one in every four cases may require antiviral drugs, the facilitation of treatment access is a rational, appropriate and cost-effective option in the management of the disease.
• The identification and accurate staging of cases of chronic hepatitis B and the judicious use of antiviral medications are predicated upon an informed and educated health workforce.
• Programmes for the population-based management of chronic hepatitis B should not be delayed until antiviral drugs become cheaper, as establishing community trust in such programmes is likely to be a lengthy and involved process. • Enhanced HCC surveillance (as above) plus specialist-led disease staging and treatment.
• Six-monthly evaluation of αFP and ultrasonographic scan of liver
• Liver biopsy to be considered
Enhanced HCC surveillance
• GP-led routine hepatitis care (as above):
Routine hepatitis care via GP
• Six-monthly evaluation of ALT, HBeAg and HBsAg
• Annual evaluation of viral load
Initial enrolment GP visit every 6 months αFP, alpha-fetoprotein; ALT, alanine aminotransferase; GP, general practitioner; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular cancer.
Notes: Levels of ALT were categorized as high when they were at least two-fold higher than the upper limit of the "normal" range. Viral loads were categorized as high when the amount of hepatitis B virus in the serum exceeded 2000 international units per ml.
